Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00450866 · ClinicalTrials.gov registry record · Phase 2
Epothilone B in Treating Patients With CNS Metastases From Breast Cancer
A Phase 2 study of Breast Cancer and Metastatic Cancer, sponsored by David Peereboom, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
- 5
- Study locations
NCT00450866 is a Phase 2 study of Breast Cancer and Metastatic Cancer that has completed, run by David Peereboom, MD. The registered enrollment target is 55 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT00450866, a Phase 2 study of Breast Cancer and Metastatic Cancer, has completed, sponsored by David Peereboom, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
- 5
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy, such as epothilone B, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well epothilone B works in treating patients with CNS metastases from breast cancer.
Conditions Studied
Interventions
- BIOLOGICAL epothilone B
Study Locations (5)
Ohio
- Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center - Cleveland
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center - Cleveland
Massachusetts
- Massachusetts General Hospital - Boston
Michigan
- University of Michigan Comprehensive Cancer Center - Ann Arbor
New York
- Memorial Sloan-Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2007-01 |
| Est. Completion | 2012-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00450866
The ClinicalTrials.gov registry entry for NCT00450866 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The listed sponsor is David Peereboom, MD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which epothilone B is the first listed.
NCT00450866 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Ohio, Massachusetts, Michigan.
Frequently Asked Questions
What is clinical trial NCT00450866 about?
NCT00450866 is a clinical study titled "Epothilone B in Treating Patients With CNS Metastases From Breast Cancer". RATIONALE: Drugs used in chemotherapy, such as epothilone B, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well epothilone B works in treating patients with CNS metastases from br...
What is the current status of trial NCT00450866?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2007-01. Estimated completion is 2012-05.
What conditions does trial NCT00450866 study?
This clinical trial studies the following conditions: Breast Cancer, Metastatic Cancer.
What interventions are being tested in trial NCT00450866?
The interventions under investigation include: epothilone B (BIOLOGICAL).
Who is sponsoring clinical trial NCT00450866?
This trial is sponsored by David Peereboom, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00450866 being conducted?
This trial has 5 study locations across Massachusetts, Michigan, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.